accueil

Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, London, and Milan, the firm brings together a team of over 45 professionals from all over Europe, the U.S., and Asia. 

The firm focuses on paradigm-shifting technologies alongside visionary entrepreneurs. Sofinnova Partners invests across the Life Sciences value chain as a lead or cornerstone investor, from very early-stage opportunities to later-stage and public companies. It has backed more than 500 companies throughout five decades, creating market leaders around the globe. Today, Sofinnova Partners has over €2 billion under management.

Sofinnova Partners invest in start-ups, early-stage companies, corporate spin-offs, and occasionally turnaround situations. The firm invests in Life Sciences (Biopharmaceuticals, Biotech, Medical Devices, Industrial Biotechnology). Sofinnova Partners proactively sources deals, takes a lead role, is most often the first institutional investor in Round A financings, and leads its portfolio companies until exit. The firm's partners sit on the boards of its portfolio companies and play an active role in the formation phase alongside entrepreneurs. Sofinnova Partners invests throughout Europe with a portion of investments made in the rest of the world.

View More

Company brings together scientific founders with leading-edge expertise in NK cells and leadership team with deep cell therapy experience   Proceeds to advance two lead CAR-NK cell therapy programs based on the company’s TAILWIND™ Platform   November 23, 2020 ...

Paris, November 20, 2020 – 07.00 CET– Pixium Vision (Euronext Growth Paris - FR0011950641), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independently, today announces it has ...

- Michelin Group and the Canadian firm Pyrowave join forces to accelerate time-to-market for an innovative plastic waste recycling technology. - They agree to fast track the process industrialization. - The purpose of the technology is to increase the rate of ...

IDE Approval Clears Path to U.S. Clinical Trial Launch for Vascular Sealant   TISSIUM, a privately-owned medtech company developing biomorphic programmable polymers for tissue reconstruction, announced today it has received approval from the U.S. Food and Drug...

● Start-up from Imperial College London and the Francis Crick Institute brings together 15 years of world-leading research on N-myristoyltransferase (NMT) and breakthrough discoveries related to its inhibition in cancer ● Initial financing of £4.5M from ventur...

Henrijette Richter

Henrijette Richter

Managing Partner

MEET OUR TEAM